An Open-label, Non-randomized, Within-patient Dose-finding Study Followed by a Double-blinded Placebo Controlled Study to Assess the Efficacy and Safety of CDZ173 in Patients With APDS/PASLI
Phase of Trial: Phase II/III
Latest Information Update: 13 Nov 2017
At a glance
- Drugs CDZ 173 (Primary)
- Indications Immunodeficiency disorders
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 07 Nov 2017 Planned End Date changed from 22 Feb 2019 to 24 May 2019.
- 07 Nov 2017 Planned primary completion date changed from 23 Jan 2019 to 24 Apr 2019.
- 02 May 2017 Planned End Date changed from 1 Apr 2019 to 21 Feb 2019.